一分钟看懂
这是一项关于Peritoneal Mesothelioma的II 期研究，登记的药物或干预包括DOMVANALIMAB + ZIMBERELIMAB；DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4，当前状态为研究进行中，已停止招募。登记地点显示中国Angers、Bordeaux、Bron、Lille等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
DOMVANALIMAB + ZIMBERELIMAB；DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Institut de Cancerologie de l'Ouest , medical oncology department · Angers
- Institut Bergonié, medical oncology department · Bordeaux
- Hospices Civils de Lyon, Thoracic Oncology Department, Louis Pradel Hospital · Bron
- Centre Hospitalier Universitaire de Lille, medical oncology department · Lille
- Hospices Civils de Lyon, Medical Oncology Department, Edouard Herriot Hospital · Lyon
- AP-HM, TIMONE Hospital, medical oncology department · Marseille
- Institut Paoli-Calmettes Marseille, medical oncology department · Marseille
- Institut Régional du Cancer de Montpellier, medical oncology department · Montpellier
- Institut Curie, thoracic oncology department · Paris
- AP-HP, Tenon Hospital, medical oncology department · Paris
- Hospices Civils de Lyon, Medical Oncology Department, Lyon SUD Hospital · Pierre-Bénite
- Centre Eugène Marquis, medical oncology department · Rennes
- Insitut de Cancérologie Strasbourg Europe, medical oncology department · Strasbourg
- ONCOPOLE Claudius Regaud, IUCT-Oncopole, medical oncology department · Toulouse
- Institut Gustave Roussy, medical oncology department · Villejuif
公开的入选条件
- General inclusion criteria for all cohorts
- * Histologically proven advanced solid tumors that progressed/resisted after minimum one line of standard systemic treatment, or resisted during the first-line of treatment
- * Participation in IMMUNORARE5 trial testing DOMVANALIMAB and ZIMBERELIMAB, validated by a multidisciplinary tumor board recognized by the national reference center, or validated by at least one national coordinator of the cohort
- * No indication of curative surgery for this disease at inclusion (For cohort 1 only (peritoneal mesothelioma), debulking surgery could be considered after minimum 6 months of study treatment in the case of important tumor response)
- * Evaluable lesions (target or non-target lesions) for radiological response according to RECIST 1.1 (cohorts 3, 4, 5), or mRECIST (cohort 1), or assessable for biological response with serum hCG (cohort 2)
- * Patients older than 18 years
- * Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- * Patients must be willing to provide an archival tumor tissue block or slides, or undergo procedure to obtain a new biopsy in absence of medical contraindication (If either a fresh biopsy or archival material is not available, patient inclusion has to be disc
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06790706；登记信息更新于 2026-06-25。